2019 Annual Report

Making big health problems a smaller part of life

“Our role is to have a positive impact on the lives of patients with poorly understood diseases. It drives every decision we make.”

Will Lewis, Chairman & CEO

We’re taking on big health challenges to make them a smaller part of patients’ lives.

Grew to more than 425 colleagues worldwide

Marked the first full year of launch for ARIKAYCE® (amikacin liposome inhalation suspension) in the U.S.

Opened a new, state-of-the-art global HQ in Bridgewater, NJ

Filed for ARIKAYCE approval in Europe and Japan